On­coSec’s de­fense of weak pre­lim­i­nary Ta­vo da­ta for PD-1 re­sis­tant melanoma can’t stop a rout

On­coSec ex­ecs may be re­gret­ting their de­ci­sion to re­lease pre­lim­i­nary Phase IIb da­ta on the com­bi­na­tion of Mer­ck’s Keytru­da and their big pipeline play Ta­vo. 

Re­searchers are re­port­ing re­sults for on­ly 9 pa­tients with metasta­t­ic melanoma at 12 weeks, and came out in a de­fen­sive pos­ture for the 2 par­tial re­spons­es they tracked at that stage in KEYNOTE-695. All of the pa­tients had seen their can­cer progress af­ter treat­ment with Op­di­vo or Keytru­da in the lead study at On­coSec.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER